Miscellaneous

Browse trials
V2  
List  

treatment    comparator  death (overall survival)  relapse  progression or death (progression free survival PFS)  Adverse events leading to treatment discontinuation objective response (ORR) Grade 3–5 drug-related AEs  Grade 3–5 drug-related AEs  serious drug-related adverse events  recurrence free survival toxic death vitiligo any grade  vitiligo grade 3-4 distant metastasis free survival aaa     
Pazopanibsarcoma, in NMA vs placebo--------------
Ipilimumabmelanoma, in adjuvant stage III only - NOVARTIS vs placebo by 28% - by 24% -- by 107% by 107% - by 24% [demonstrated]--- by 24% -
Nivolumabmelanoma, in adjuvant stage III only - NOVARTIS vs ipilimumab-- by 35% ----- by 35% --- by 27% -
Pembrolizumabmelanoma, in adjuvant stage III only - NOVARTIS vs placebo-- by 43% -- by 335% by 335% - by 43% [demonstrated]- by 196% NS--
Vemurafenibmelanoma, in adjuvant stage III only - NOVARTIS vs placebo--NS-----NS---NS-
Trametinib + dabrafenib melanoma, in adjuvant stage III only - NOVARTIS vs placebo by 43% - by 53% ---------- by 49%
Interferon alphamelanoma, in adjuvant stage III only - NOVARTIS vs observationNS- by 13% ---------NS-

 


- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons